Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yuhan Corporation
New Korea Vaccine Funds Eye Broad Industry Benefits, Partnerships
Yuanta Investment, which will launch one of two major new public/private biopharma support funds in South Korea later this year, talks about the strategy behind the initiative and the plans for diverse collaborations with pharma companies both at home and abroad.
The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
Will The Dark Tunnel For Korean Biopharmas End In 2023?
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
- Generic Drugs
- Drug Discovery Tools
- Other Names / Subsidiaries
- Yuhan USA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.